The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients.
The relative safety of imipenem/cilastatin for 3470 patients was reviewed to see if the safety profile was similar to that seen for the first 1723 patients treated. The most common clinical adverse experiences were local ones related to the site of intravenous infusion. Gastrointestinal adverse experiences included nausea, vomiting, or diarrhoea. The frequency of pseudomembranous colitis was low (0 X 1%). The most common central nervous system abnormality was seizure. The most common background factor was central nervous system abnormality including prior history of seizure. Dermatological adverse experiences included rash, pruritus and urticaria. Bleeding and decreased renal function were uncommon. The most common laboratory changes included transient increased liver function values, eosinophilia, positive Coombs' test (not associated with haemolysis) and increased platelets. The current clinical and laboratory safety data are similar to those obtained in the early part of the clinical trials.
Calandra
G B
GB
Wang
C
C
Aziz
M
M
Brown
K R
KR
D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy; D001772:Blood Cell Count; D015377:Cilastatin; D003521:Cyclopropanes / Q000009:adverse effects* / Q000627:therapeutic use; D004150:Dipeptidases / Q000037:antagonists & inhibitors*; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D015378:Imipenem; D013845:Thienamycins / Q000009:adverse effects* / Q000627:therapeutic use
D003521:Cyclopropanes; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; D004150:Dipeptidases